US2020172522A1PendingUtilityA1
Methods for preparing oltipraz
Est. expiryJun 25, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Bomi Framroze
C07D 241/12C07D 409/04C07D 241/24A61K 31/497A61P 33/12A61P 39/02
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides improved methods of synthesizing oltipraz, which result in higher overall yield and better purity of the desired product.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A method of making a composition comprising oltipraz, comprising the steps of:
(i) reacting a quantity of pyrazine-2-carboxylic acid methyl ester with methyl propionate to form methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate, wherein the reaction is carried out in the presence of a base comprising potassium t-butoxide or sodium pentanoate, and a solvent comprising 1,4-dioxane in tetrahydrofuran (THF), wherein the ratio of 1,4-dioxane in the THF is at least about 1:5; (ii) adding at least one aqueous liquid to quench the reaction in Step (i); (iii) adding a nonpolar organic solvent and an ionic salt, thereby forming a composition comprising an aqueous component and an organic component, wherein the organic component comprises the nonpolar solvent and methyl 2-methyl-3-oxo-3-(pyrazin-2-yl) propanoate; (iv) separating the organic component from the aqueous component; (v) reacting the methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate ester in the organic component with P 2 S 5 in the presence of a nonpolar organic solvent to form 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione (oltipraz).
22 . A method according to claim 21 , wherein the ratio of 1,4-dioxane to THF in Step (i) is from about 1:5 to about 1:3.
23 . A method according to claim 22 , wherein, the ratio of 1,4-dioxane to THF is about 1:4.
24 . A method according to claim 21 , wherein the base comprises potassium t-butoxide.
25 . A method according to claim 21 , wherein the mole ratio of the base to methyl propionate is from about 3:1 to about 1:1.
26 . A method according to claim 21 , wherein the nonpolar organic solvent used in Step (iii) comprises toluene.
27 . A method according to claim 21 , wherein the nonpolar organic solvent in Step (v) comprises toluene.
28 . A method according to claim 21 , wherein the nonpolar solvent in Step (iii) is the same nonpolar solvent used in Step (v).
29 . A method according to claim 21 , wherein the yield of oltipraz is greater than 21% based on the amount of pyrazine-2-carboxylic acid methyl ester.
30 . A composition comprising oltipraz prepared by the process of claim 21 .
31 . A method of making a purified oltipraz composition, comprising the steps of:
(i) reacting a quantity of pyrazine-2-carboxylic acid methyl ester with methyl propionate to form methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate, wherein the reaction is carried out in the presence of a base comprising potassium t-butoxide or sodium pentanoate, and a solvent comprising 1,4-dioxane in tetrahydrofuran (THF), wherein the ratio of 1,4-dioxane in the THF is at least about 1:5; (ii) adding at least one aqueous liquid to quench the reaction in Step (i); (iii) adding a nonpolar organic solvent and an ionic salt, thereby forming a composition comprising an aqueous component and an organic component, wherein the organic component comprises the nonpolar solvent and methyl 2-methyl-3-oxo-3-(pyrazin-2-yl) propanoate; (iv) separating the organic component from the aqueous component; (v) reacting the methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate ester in the organic component with P 2 S 5 in the presence of a nonpolar organic solvent to form 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione (oltipraz); (vi) quenching the reaction with an aqueous composition to yield a composition comprising (i) an aqueous component and (ii) an organic component that comprises oltipraz; (vii) separating the organic component comprising oltipraz to yield an organic composition comprising oltipraz in the nonpolar organic solvent; (viii) reducing the amount of solvent in the organic composition; (ix) precipitating the oltipraz in the organic composition to yield a composition comprising oltipraz; (x) separating the precipitated oltipraz; and (xi) purifying the separated oltipraz precipitate.
32 . A method according to claim 31 , wherein the ratio of 1,4-dioxane to THF in Step (i) is from about 1:5 to about 1:3.
33 . A method according to claim 31 , wherein step (viii) comprises evaporating at least a portion of the solvent in the organic composition, step (ix) comprises adding to the organic composition a solvent that causes the oltipraz to precipitate, and step (x) comprises separating the oltipraz by filtering.
34 . A method according to claim 31 , wherein the step of purifying comprises recrystallization, and excludes purification that comprises chromatographic separation.
35 . A method of making a composition comprising methyl 2-methyl-3-oxo-3-(pyrazin-2-yl), comprising the step of
(i) reacting a quantity of pyrazine-2-carboxylic acid methyl ester with methyl propionate to form methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate, wherein the reaction is carried out in the presence of a base comprising potassium t-butoxide or sodium pentanoate, and a solvent comprising 1,4-dioxane in tetrahydrofuran (THF), wherein the ratio of 1,4-dioxane in the THF is at least about 1:5.
36 . A method according to claim 35 , wherein the yield of methyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate is greater than 80% based on the amount of pyrazine-2-carboxylic acid methyl ester.
37 . A method according to claim 35 , further comprising the step of adding at least one aqueous liquid to quench the reaction in Step (i), thereby forming a composition comprising an organic component and an aqueous component.
38 . A method according to claim 37 , further comprising the step of separating the organic component from the aqueous component to yield a composition comprising the organic component.
39 . A composition made by the method of claim 37 .
40 . A composition made by the method of claim 38 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.